• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

使用胰腺导管腺癌细胞系构建的新型原位腹膜播散小鼠模型的建立及生物学分析

Development and Biological Analysis of a Novel Orthotopic Peritoneal Dissemination Mouse Model Generated Using a Pancreatic Ductal Adenocarcinoma Cell Line.

作者信息

Yanagihara Kazuyoshi, Kubo Takanori, Mihara Keichiro, Kuwata Takeshi, Ochiai Atsushi, Seyama Toshio, Yokozaki Hiroshi

机构信息

Department of Life Sciences, Yasuda Women's University Faculty of Pharmacy.

Department of Hematology/Oncology, Research Institute for Radiation Biology and Medicine, Hiroshima University, Hiroshima.

出版信息

Pancreas. 2019 Mar;48(3):315-322. doi: 10.1097/MPA.0000000000001253.

DOI:10.1097/MPA.0000000000001253
PMID:30747829
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC6426353/
Abstract

OBJECTIVES

Peritoneal dissemination (PD) is an important cause of morbidity and mortality among patients with pancreatic ductal adenocarcinoma (PDAC). We sought to develop and characterized a novel PD mouse model by using a previously established PDAC cell line TCC-Pan2.

METHODS

TCC-Pan2 cell line was characterized for growth rate, tumor markers, histology, and somatic mutations. TCC-Pan2 cells were implanted orthotopically to produce PD. TCC-Pan2 cells from these metastatic foci were expanded in vitro and then implanted orthotopically in mice. This PD model was used for comparing the antitumor effect of paclitaxel and NK105.

RESULTS

Orthotopically implanted TCC-Pan2 cells caused tumor formation and PD with high frequency in mice. A potent metastatic subline-Pan2M-was obtained. NK105 exerted a stronger antitumor effect than paclitaxel against Pan2M cells harboring a luciferase gene (Pan2MmLuc). Notably, the survival rate on day 80 in the Pan2MmLuc mouse model was 100% for the NK105 group and 0% for the paclitaxel group.

CONCLUSION

TCC-Pan2 cell line and Pan2MmLuc PD model can serve as useful tools for monitoring the responses to antineoplastic agents and for studying PDAC biology.

摘要

目的

腹膜播散(PD)是胰腺导管腺癌(PDAC)患者发病和死亡的重要原因。我们试图通过使用先前建立的PDAC细胞系TCC-Pan2来开发并表征一种新型的PD小鼠模型。

方法

对TCC-Pan2细胞系进行生长速率、肿瘤标志物、组织学和体细胞突变方面的表征。将TCC-Pan2细胞原位植入以产生PD。从这些转移灶中获取的TCC-Pan2细胞在体外扩增,然后原位植入小鼠体内。该PD模型用于比较紫杉醇和NK105的抗肿瘤效果。

结果

原位植入的TCC-Pan2细胞在小鼠中高频诱导肿瘤形成和PD。获得了一个高转移性亚系——Pan2M。NK105对携带荧光素酶基因的Pan2M细胞(Pan2MmLuc)的抗肿瘤作用比紫杉醇更强。值得注意的是,在Pan2MmLuc小鼠模型中,第80天时NK105组的生存率为100%,紫杉醇组为0%。

结论

TCC-Pan2细胞系和Pan2MmLuc PD模型可作为监测抗肿瘤药物反应和研究PDAC生物学的有用工具。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/b1a5/6426353/a864b3ab21b8/mpa-48-315-g005.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/b1a5/6426353/30c809cf775d/mpa-48-315-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/b1a5/6426353/a864b3ab21b8/mpa-48-315-g005.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/b1a5/6426353/30c809cf775d/mpa-48-315-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/b1a5/6426353/a864b3ab21b8/mpa-48-315-g005.jpg

相似文献

1
Development and Biological Analysis of a Novel Orthotopic Peritoneal Dissemination Mouse Model Generated Using a Pancreatic Ductal Adenocarcinoma Cell Line.使用胰腺导管腺癌细胞系构建的新型原位腹膜播散小鼠模型的建立及生物学分析
Pancreas. 2019 Mar;48(3):315-322. doi: 10.1097/MPA.0000000000001253.
2
EGCG inhibits growth of human pancreatic tumors orthotopically implanted in Balb C nude mice through modulation of FKHRL1/FOXO3a and neuropilin.EGCG 通过调节 FKHRL1/FOXO3a 和神经纤毛蛋白抑制 Balb C 裸鼠原位移植的人胰腺肿瘤的生长。
Mol Cell Biochem. 2013 Jan;372(1-2):83-94. doi: 10.1007/s11010-012-1448-y. Epub 2012 Sep 13.
3
Clinical, molecular and genetic validation of a murine orthotopic xenograft model of pancreatic adenocarcinoma using fresh human specimens.使用新鲜人类标本对胰腺腺癌小鼠原位异种移植模型进行临床、分子和基因验证。
PLoS One. 2013 Oct 18;8(10):e77065. doi: 10.1371/journal.pone.0077065. eCollection 2013.
4
MutY-Homolog (MYH) inhibition reduces pancreatic cancer cell growth and increases chemosensitivity.MutY同源物(MYH)抑制可降低胰腺癌细胞的生长并增加化学敏感性。
Oncotarget. 2017 Feb 7;8(6):9216-9229. doi: 10.18632/oncotarget.13985.
5
Antitumor effect and pharmacokinetics of intraperitoneal NK105, a nanomicellar paclitaxel formulation for peritoneal dissemination.腹腔内 NK105(一种用于腹腔转移的纳米胶束紫杉醇制剂)的抗肿瘤作用及药代动力学研究。
Cancer Sci. 2012 Jul;103(7):1304-10. doi: 10.1111/j.1349-7006.2012.02274.x. Epub 2012 Apr 19.
6
Bisphosphonates inhibit stellate cell activity and enhance antitumor effects of nanoparticle albumin-bound paclitaxel in pancreatic ductal adenocarcinoma.双膦酸盐可抑制星状细胞活性,并增强纳米白蛋白结合型紫杉醇在胰腺导管腺癌中的抗肿瘤作用。
Mol Cancer Ther. 2014 Nov;13(11):2583-94. doi: 10.1158/1535-7163.MCT-14-0028. Epub 2014 Sep 5.
7
A tunable delivery platform to provide local chemotherapy for pancreatic ductal adenocarcinoma.一种用于为胰腺导管腺癌提供局部化疗的可调节递送平台。
Biomaterials. 2016 Jul;93:71-82. doi: 10.1016/j.biomaterials.2016.03.044. Epub 2016 Mar 31.
8
Enhancing Nab-Paclitaxel Delivery Using Microbubble-Assisted Ultrasound in a Pancreatic Cancer Model.利用微泡辅助超声增强胰腺癌模型中 Nab-紫杉醇的递送。
Mol Pharm. 2019 Sep 3;16(9):3814-3822. doi: 10.1021/acs.molpharmaceut.9b00416. Epub 2019 Aug 6.
9
MicroRNA-323-3p inhibits cell invasion and metastasis in pancreatic ductal adenocarcinoma via direct suppression of SMAD2 and SMAD3.微小RNA-323-3p通过直接抑制SMAD2和SMAD3抑制胰腺导管腺癌的细胞侵袭和转移。
Oncotarget. 2016 Mar 22;7(12):14912-24. doi: 10.18632/oncotarget.7482.
10
Sonoporation with Acoustic Cluster Therapy (ACT®) induces transient tumour volume reduction in a subcutaneous xenograft model of pancreatic ductal adenocarcinoma.声孔作用联合声团聚治疗(ACT®)可使胰腺导管腺癌皮下移植瘤体积暂时缩小。
J Control Release. 2017 Jan 10;245:70-80. doi: 10.1016/j.jconrel.2016.11.019. Epub 2016 Nov 18.

引用本文的文献

1
Biomimetic Tumour Model Systems for Pancreatic Ductal Adenocarcinoma in Relation to Photodynamic Therapy.用于胰腺导管腺癌光动力治疗的仿生肿瘤模型系统
Int J Mol Sci. 2025 Jul 2;26(13):6388. doi: 10.3390/ijms26136388.
2
Involvement of clusterin expression in the refractory response of pancreatic cancer cells to a MEK inhibitor.簇集蛋白表达参与胰腺癌细胞对 MEK 抑制剂的难治性反应。
Cancer Sci. 2023 May;114(5):2189-2202. doi: 10.1111/cas.15735. Epub 2023 Feb 9.
3
Expanding the Spectrum of Pancreatic Cancers Responsive to Vesicular Stomatitis Virus-Based Oncolytic Virotherapy: Challenges and Solutions.

本文引用的文献

1
Mechanisms of peritoneal dissemination in gastric cancer.胃癌腹膜播散的机制
Oncol Lett. 2017 Dec;14(6):6991-6998. doi: 10.3892/ol.2017.7149. Epub 2017 Oct 9.
2
KRAS, TP53, CDKN2A, SMAD4, BRCA1, and BRCA2 Mutations in Pancreatic Cancer.胰腺癌中的KRAS、TP53、CDKN2A、SMAD4、BRCA1和BRCA2突变
Cancers (Basel). 2017 Apr 28;9(5):42. doi: 10.3390/cancers9050042.
3
An in vivo mechanism for the reduced peripheral neurotoxicity of NK105: a paclitaxel-incorporating polymeric micellar nanoparticle formulation.NK105降低外周神经毒性的体内机制:一种载有紫杉醇的聚合物胶束纳米颗粒制剂
扩大对基于水疱性口炎病毒的溶瘤病毒疗法有反应的胰腺癌谱:挑战与解决方案
Cancers (Basel). 2021 Mar 9;13(5):1171. doi: 10.3390/cancers13051171.
4
Mouse Models of Peritoneal Carcinomatosis to Develop Clinical Applications.用于临床应用开发的腹膜癌病小鼠模型。
Cancers (Basel). 2021 Feb 25;13(5):963. doi: 10.3390/cancers13050963.
5
Preclinical mouse models for immunotherapeutic and non-immunotherapeutic drug development for pancreatic ductal adenocarcinoma.用于胰腺导管腺癌免疫治疗和非免疫治疗药物研发的临床前小鼠模型。
Ann Pancreat Cancer. 2020 Jul;3. doi: 10.21037/apc.2020.03.03. Epub 2020 Jul 22.
Int J Nanomedicine. 2017 Feb 15;12:1293-1304. doi: 10.2147/IJN.S114356. eCollection 2017.
4
Utility of Assessing the Number of Mutated KRAS, CDKN2A, TP53, and SMAD4 Genes Using a Targeted Deep Sequencing Assay as a Prognostic Biomarker for Pancreatic Cancer.使用靶向深度测序检测评估KRAS、CDKN2A、TP53和SMAD4基因突变数量作为胰腺癌预后生物标志物的效用
Pancreas. 2017 Mar;46(3):335-340. doi: 10.1097/MPA.0000000000000760.
5
Pancreatic cancer cell lines as patient-derived avatars: genetic characterisation and functional utility.作为患者来源替身的胰腺癌细胞系:基因特征与功能效用
Gut. 2018 Mar;67(3):508-520. doi: 10.1136/gutjnl-2016-313133. Epub 2017 Jan 10.
6
Multicenter Phase II Study of Intravenous and Intraperitoneal Paclitaxel With S-1 for Pancreatic Ductal Adenocarcinoma Patients With Peritoneal Metastasis.多中心II期研究:静脉及腹腔注射紫杉醇联合S-1用于治疗伴有腹膜转移的胰腺导管腺癌患者
Ann Surg. 2017 Feb;265(2):397-401. doi: 10.1097/SLA.0000000000001705.
7
Cancer Statistics, 2017.《2017 年癌症统计》
CA Cancer J Clin. 2017 Jan;67(1):7-30. doi: 10.3322/caac.21387. Epub 2017 Jan 5.
8
Comprehensive screening of target molecules by next-generation sequencing in patients with malignant solid tumors: guiding entry into phase I clinical trials.通过下一代测序对恶性实体瘤患者进行靶分子综合筛查:指导进入I期临床试验。
Mol Cancer. 2016 Nov 16;15(1):73. doi: 10.1186/s12943-016-0553-z.
9
Molecular mechanisms of peritoneal dissemination in gastric cancer.胃癌腹膜播散的分子机制
World J Gastroenterol. 2016 Aug 14;22(30):6829-40. doi: 10.3748/wjg.v22.i30.6829.
10
Peritoneal dissemination in early gastric cancer: importance of the lymphatic route.早期胃癌的腹膜播散:淋巴途径的重要性
Virchows Arch. 2016 Aug;469(2):155-61. doi: 10.1007/s00428-016-1960-7. Epub 2016 May 25.